Investors remain optimistic about Patterson Companies on the back of its broad product line.

Investors remain optimistic about Patterson Companies on the back of its broad product line.

STE's strong prospects in the healthcare business arm bode well for investors.

RVTY's strong product portfolio raises optimism about the stock.

QDEL's strong product portfolio raises optimism about the stock.

NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.

NJR makes a strong case for investment, given its growth prospects, strong ROE and capability to increase shareholders' value.

NWN makes a strong case for investment, given its growth prospects, better debt management and capability to increase shareholders' value.